Eli Lilly Surges After All Three Major PBMs Agree to Cover Its Full Obesity Drug Lineup

Benzinga reported Thursday that Eli Lilly and Company (NYSE: LLY) shares climbed roughly 3.5% to approximately $1,120 during regular trading, approaching the stock’s 52-week peak near $1,134. The catalyst was a sweeping insurance announcement that dramatically widens patient access to the pharmaceutical giant’s weight-management medicines.

PBM Deal Unlocks Mass Market Access for Obesity Lineup

All three of America’s largest pharmacy benefit managers have committed to covering Lilly’s complete obesity drug portfolio under their commercial plan templates. The agreement represents a significant commercial inflection point for a company that has staked much of its near-term growth on the booming weight-loss drug market.

Lilly executive vice president and president of Lilly USA, Ilya Yuffa, said effective obesity treatment has long been financially out of reach for the patients who need it most. Under the newly structured commercial templates, eligible patients can obtain the medications for just $25 per month. Select Medicare Part D beneficiaries will gain access at $50 monthly through a dedicated GLP-1 bridge program, beginning July 1.

Rollout Follows a Phased Timeline

The coverage expansion will not happen all at once. Lilly’s once-daily oral obesity pill, Foundayo, becomes eligible under the CVS Caremark Commercial Template starting June 1. Coverage for the injectable option, Zepbound, resumes more broadly under standard template plans from October 1. Current Zepbound patients will experience no gap in coverage during the transition period.

Background: Lilly’s GLP-1 Bet Has Reshaped the Company

Lilly entered the GLP-1 obesity market later than rival Novo Nordisk but has moved aggressively to close the gap through both product development and distribution partnerships. Zepbound, which targets dual hormone receptors, has posted strong sales growth since its launch, and the addition of an oral formulation in Foundayo has expanded the addressable patient pool considerably.

Technical Picture Shows Stretched But Sustained Momentum

From a price-action standpoint, LLY has run well ahead of its key moving averages. The stock sits more than 21% above its 200-day simple moving average, and the relative strength index has crossed the 70 threshold, signaling technically overbought conditions. A golden cross formed in November 2025 remains intact, providing a constructive longer-term framework. Broad market momentum also provided a tailwind, with the Nasdaq up roughly 0.83% and the S&P 500 gaining around 0.51% on the day.

Key resistance stands near $1,134. Meaningful support sits around $943.

Read Next: Fed Holds Rates Steady as Inflation Data Stays Stubborn